Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
![Current Oncology | Free Full-Text | Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future Current Oncology | Free Full-Text | Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future](https://www.mdpi.com/curroncol/curroncol-29-00050/article_deploy/html/images/curroncol-29-00050-g001.png)
Current Oncology | Free Full-Text | Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
![Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420325904-gr3.jpg)
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect
![Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/1af44a9d-ec7d-47e0-8a7d-b299bfde3ff0/gr1.gif)
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
![Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/7/1/253/F2.large.jpg)
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions
![Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420325904-gr1.jpg)
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - ScienceDirect
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1 FGFR2 or FGFR3- (FUZE Clinical Trial) | Clinical Research Trial Listing ( Solid Tumor ) ( NCT03834220 )
![Cells | Free Full-Text | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma Cells | Free Full-Text | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma](https://pub.mdpi-res.com/cells/cells-09-00688/article_deploy/html/images/cells-09-00688-g003.png?1585752712)
Cells | Free Full-Text | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
![Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer | Nature Reviews Clinical Oncology Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer | Nature Reviews Clinical Oncology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41571-021-00579-w/MediaObjects/41571_2021_579_Fig1_HTML.png)
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer | Nature Reviews Clinical Oncology
![FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020 FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020](https://journals.sagepub.com/cms/10.1177/1758835920953293/asset/images/large/10.1177_1758835920953293-fig1.jpeg)
FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020
![Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review](https://assets.cureus.com/uploads/figure/file/391204/lightbox_532e0970e69e11ec94005344a2fa809d-Screenshot-2022-06-07-at-15.12.12.png)
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review
![FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020 FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020](https://journals.sagepub.com/cms/10.1177/1758835920953293/asset/images/large/10.1177_1758835920953293-fig2.jpeg)
FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020
![Frontiers | Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives Frontiers | Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives](https://www.frontiersin.org/files/Articles/860453/fonc-12-860453-HTML/image_m/fonc-12-860453-g001.jpg)
Frontiers | Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives
![Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review](https://assets.cureus.com/uploads/figure/file/371227/lightbox_256708d0c9f611ecbc0e452d0934a085-Screenshot-2022-05-02-at-11.59.13.png)
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review
![Cancers | Free Full-Text | Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm Cancers | Free Full-Text | Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm](https://www.mdpi.com/cancers/cancers-12-02039/article_deploy/html/images/cancers-12-02039-g001-550.jpg)